The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review
Open Access
Abstract
Introduction Homonymous hemianopia is a common and disabling visual problem after stroke. Currently, prism glasses and visual scanning training are proposed to improve it. The aim of this trial is to determine the effectiveness of these interventions compared to standard care. Methods and analysis The trial will be a multicentre three arm individually randomised controlled trial with independent assessment at 6 week, 12 week and 26 week post-randomisation. Recruitment will occur in hospital, outpatient and primary care settings in UK hospital trusts. A total of 105 patients with homonymous hemianopia and without ocular motility impairment, visual inattention or pre-existent visual field impairment will be randomised to one of three balanced groups. Randomisation lists will be stratified by site and hemianopia level (partial or complete) and created using simple block randomisation by an independent statistician. Allocations will be disclosed to patients by the treating clinician, maintaining blinding for outcome assessment. The primary outcome will be change in visual field assessment from baseline to 26 weeks. Secondary measures will include the Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham Extended Activities of Daily Living, Euro Qual-5D and Short Form-12 questionnaires. Analysis will be by intention to treat. Ethics and dissemination This study has been developed and supported by the UK Stroke Research Network Clinical Studies Group working with service users. Multicentre ethical approval was obtained through the North West 6 Research ethics committee (Reference 10/H1003/119). The trial is funded by the UK Stroke Association. Trial Registration: Current Controlled Trials ISRCTN05956042. Dissemination will consider usual scholarly options of conference presentation and journal publication in addition to patient and public dissemination with lay summaries and articles. Trial Registration Current Controlled Trials ISRCTN05956042.Keywords
This publication has 118 references indexed in Scilit:
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmology, 2011
- Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edemaClinical Ophthalmology, 2011
- ROLE OF INTRAVITREAL BEVACIZUMAB IN EALES DISEASE WITH DENSE VITREOUS HEMORRHAGERetina, 2011
- A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medicationsEye, 2011
- Comparison of the Short-Term Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection for Diabetic Macular EdemaKorean Journal of Ophthalmology, 2011
- A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edemaMiddle East African Journal of Ophthalmology, 2010
- Comparison Between Intravitreal Bevacizumab and Triamcinolone for Macular Edema Secondary to Branch Retinal Vein OcclusionKorean Journal of Ophthalmology, 2009
- Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term resultsOman Journal of Ophthalmology, 2009
- A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular EdemaOphthalmology, 2007
- Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessBritish Journal of Ophthalmology, 2007